BC Innovations | May 8, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | May 6, 2019
Distillery Therapeutics

Chlorobenzamide-based activator of SOD3 to treat osteoarthritis

DISEASE CATEGORY: Autoimmune disease INDICATION: Osteoarthritis Cell culture and rat studies identified a chlorobenzamide-based SOD3 activator that could help treat osteoarthritis (OA). Screening of a small molecule library in mouse chondrocyte-based activity assays yielded a...
BC Innovations | Apr 10, 2019
Distillery Techniques

Method for generating CPS-based glycoconjugates for pneumococcal vaccines

TECHNIQUES CATEGORY: Drug platforms TECHNOLOGY: Conjugates An E. coli -based method for generating S. pneumoniae CPS-based glycoconjugates could be used to produce pneumococcal vaccines. Generation of the glycoconjugates involves expressing three factors in E. coli...
BC Innovations | Apr 11, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Mutations in COMP and CHADL could help predict the risk of hip osteoarthritis. Genome-wide association studies in 4,657 patients and 207,514 healthy volunteers identified independent associations between the disease and a missense...
BioCentury | Dec 7, 2015
Regulation

Adapting registries

After years of asking drug companies to collect postmarket safety data via registries, EMA has come to the conclusion that duplication of efforts among companies and the resulting differences in standards are limiting the usefulness...
BC Extra | Oct 8, 2015
Politics & Policy

EMA's COMP reelects chair, vice-chair

EMA's Committee for Orphan Medicinal Products reappointed Bruno Sepodes as chair and Lesley Greene as vice-chair. Each will serve a new three-year term that begins this month....
BC Extra | Nov 18, 2014
Top Story

Juno files for IPO

Less than a year after Juno Therapeutics Inc. (Seattle, Wash.) debuted with a massive series A round, the cancer immunotherapy play is looking to go public. The company on Monday filed to raise up to...
BC Innovations | Jul 24, 2014
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Cartilage oligomeric matrix protein (COMP) epitopes as markers of pathological joint degeneration Newly identified COMP epitopes could be useful as markers for monitoring pathological cartilage degeneration...
BC Week In Review | May 26, 2014
Clinical News

MOR00208 regulatory update

MorphoSys said FDA granted Orphan Drug designation to MOR208 to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The company also said it received a positive opinion from EMA's COMP to grant Orphan...
BioCentury | May 26, 2014
Finance

Highlights of weekly biotech stock moves

Regulatory milestones AB Science S.A. (Euronext:AB) was up €0.29 to €11.32 on Friday after EMA's CHMP reiterated its recommendation against conditional approval of Masiviera masitinib for first-line treatment of non-resectable locally advanced or metastatic pancreatic...
Items per page:
1 - 10 of 260